Gregg Alton - Gilead Sciences EVP
| GILD Stock | USD 66.93 0.38 0.56% |
EVP
Mr. Gregg H. Alton is no longer Chief Patient Officer of Gilead Sciences Inc., effective October 4, 2019. Mr. Alton is responsible for the companys strategy, growth and operations. As Chief Patient Officer, he leads Gileads patient outreach and engagement initiatives and the companys efforts to facilitate access to its medicines around the world. He oversees Gileads corporate and medical affairs functions and developing world access programs, as well as its digital patient solutions and patientcentered outcomes groups and commercial operations in certain countries. Since joining Gilead in 1999, Mr. Alton has held a number of positions at the company with experience in legal, medical affairs, policy and commercial. He previously served as Interim Chief Executive Officer and General Counsel. Prior to joining Gilead, he was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the board of directors of the AIDS Institute, the Boys and Girls Clubs of Oakland, and the Partners in Health Board of Trustees. He serves on the U.S. governments Industry Trade Advisory Committee on Intellectual Property Rights and the advisory boards for UCSF Global Health Group, USC Schaeffer Center for Health Policy and Economics and the UC Berkeley College of Letters and Science. He is also a member of the board of directors of Collidion, Inc since 2019.
| Age | 52 |
| Tenure | 5 years |
| Address | 333 Lakeside Drive, Foster City, CA, United States, 94404 |
| Phone | 650 574 3000 |
| Web | https://www.gilead.com |
Gilead Sciences Management Efficiency
The company has return on total asset (ROA) of 0.0978 % which means that it generated a profit of $0.0978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2554 %, meaning that it created $0.2554 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.22. The current year's Return On Capital Employed is expected to grow to 0.19. At present, Gilead Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.9 B, whereas Total Current Assets are forecasted to decline to about 10.8 B.Similar Executives
| Found 5 records | EVP Age | ||
| Madhavan Balachandran | Amgen Inc | 64 | |
| Clark Golestani | Merck Company | 48 | |
| Laura Schumacher | AbbVie Inc | 61 | |
| David Smith | AstraZeneca PLC ADR | 50 | |
| Anthony Hooper | Amgen Inc | 62 | |
Management Performance
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0978 |
Gilead Sciences Leadership Team
Elected by the shareholders, the Gilead Sciences' board of directors comprises two types of representatives: Gilead Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gilead. The board's role is to monitor Gilead Sciences' management team and ensure that shareholders' interests are well served. Gilead Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gilead Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathleen Watson, Executive Vice President - Human Resources | ||
| John McHutchison, Executive Vice President - Clinical Research | ||
| Andrew Cheng, Executive Vice President - HIV Therapeutics and Development Operations | ||
| John Martin, Chairman and CEO | ||
| Andrew Dickinson, Executive Vice President - Corporate Development and Strategy | ||
| Michael Quigley, VP Biology | ||
| Linda Higgins, Innovation Research | ||
| Gayle Wilson, Independent Director | ||
| Daniel ODay, Chairman of the Board, CEO | ||
| Jacqueline Barton, Director | ||
| Brett Pletcher, Executive VP and General Counsel | ||
| William Lee, Executive Vice President - Research | ||
| Deborah Telman, General Affairs | ||
| John Madigan, Independent Director | ||
| Martin Silverstein, Executive Vice President - Strategy | ||
| Kevin Lofton, Independent Director | ||
| Jacquie CFA, Vice Relations | ||
| Paul Carter, Executive Vice President - Commercial Operations | ||
| Gregg Alton, Executive VP of Corporate and Medical Affairs and Secretary | ||
| Diana Brainard, Senior Vice President HIV and Emerging Viral Infections | ||
| Flavius MD, Executive Research | ||
| Carla Hills, Independent Director | ||
| John Cogan, Lead Independent Director | ||
| Sandra Patterson, Corporate VP | ||
| John Milligan, Pres and COO | ||
| Nicholas Moore, Independent Director | ||
| James Meyers, Executive Vice President - Worldwide Commercial Operations | ||
| Katie Watson, Executive Vice President of Human Resources | ||
| Kelly Kramer, Director | ||
| Johanna Mercier, Chief Commercial Officer | ||
| Jyoti Mehra, Executive Vice President of Human Resources | ||
| Laura Hamill, Executive Vice President - Worldwide Commercial Operations | ||
| Robin Washington, CFO and Executive VP | ||
| Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandD | ||
| Per WoldOlsen, Independent Director | ||
| Harish Manwani, Director | ||
| Taiyin Yang, Executive Vice President - Pharmaceutical Development and Manufacturing | ||
| Kevin Young, COO | ||
| Etienne Davignon, Independent Director | ||
| Richard Whitley, Independent Director | ||
| Diane Wilfong, Corp VP | ||
| Rudolf Ertl, Canada, Australia |
Gilead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gilead Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0978 | ||||
| Profit Margin | 0.21 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 101.08 B | ||||
| Shares Outstanding | 1.25 B | ||||
| Shares Owned By Institutions | 88.37 % | ||||
| Number Of Shares Shorted | 22.57 M | ||||
| Price To Earning | 359.42 X | ||||
| Price To Book | 3.72 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 3 | Earnings Share 4.5 | Revenue Per Share 21.728 | Quarterly Revenue Growth (0.04) |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.